Cubist price target raised to $90 from $80 at Leerink Leerink raised its price target for Cubist Pharmaceuticals shares to $90 after its survey of Pharmacy Directors indicated less potential Sivextro price erosion once Zyvox becomes generic than it previously assumed. The firm keeps an Outperform rating on the stock.
News For CBST From The Last 14 Days
Check below for free stories on CBST the last two weeks.
Cubist annouces EMA acceptance of ceftolozane, tazobactam MAA Cubist announced that the European Medicines Agency has accepted for review the company’s Marketing Authorization Application for its investigational antibiotic ceftolozane, tazobactam. Cubist is seeking approval of ceftolozane/tazobactam for the treatment of complicated urinary tract Infections and complicated intra-abdominal infections, with a decision from the European Commission expected during 1H15. The MAA submission is based on positive data from two pivotal Phase 3 clinical trials of ceftolozane, tazobactam in complicated urinary tract infections and complicated intra-abdominal infections. These studies met both the EMA and U.S. Food and Drug Administration specified primary endpoints. Results of the secondary analyses were consistent with and supportive of the primary outcomes.